Please login to the form below

I have forgotten my password

Strattera

This page shows the latest Strattera news and features for those working in and with pharma, biotech and healthcare.

Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

Strattera (atomoxetine) and erectile dysfunction therapy Cialis (tadalafil).

Latest news

Shire launches long-acting ADHD drug Intuniv in UK

It is also the first alternative to Eli Lilly's non-stimulant ADHD therapy Strattera (atomoxetine) in Europe, providing another option for the approximately 10% of people with the condition who
Lilly feels effects of Cymbalta competition

to $588m and attention-deficit hyperactivity disorder (ADHD) drug Strattera (atomoxetine) brought in $201m, up 23 per cent.
Scotland first in UK to back Pfizer's Inlyta

month - along with Roche's Lucentis (ranibizumab) for pathologic myopia and Eli Lilly's attention deficit hyperactivity disorder (ADHD) therapy Strattera (atomoxetine).
Lilly’s Strattera wins new adult ADHD licence in UK

Lilly’ s Strattera wins new adult ADHD licence in UK. On course for wider EU approval for adults yet to receive treatment. ... Strattera's new licence is backed by results from clinical trials that demonstrate it can achieve significant improvements in
Lilly's Strattera patent upheld in US

The US court of appeals has upheld the validity of Eli Lilly &Company's patent for attention deficit hyperactivity disorder (ADHD) drug Strattera (atomoxetine). ... However, the most recent decision upholds Lilly's method-of-use patent which provides

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest Intelligence

Challenging perceptions

These classes were methylphenidate-based products like Johnson &Johnson's Concerta (methylphenidate hydrochloride) and Lilly's non-stimulant Strattera (atomoxetine).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Medical Writer: Great salary and bebefits

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Project Manager, Medical Communications, London: Excellent Salary

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Medical Writer, e-learning/ training, London: Excellent Salary

Senior Programme Executive: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Scientific Director: Great salary and bebefits

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Account Manager – Med Comms – London: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Project Manager, Medical Communications, Oxford: Excellent Salary

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Editor – Medical Education Agency – Bucks: Salary TBC

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Medical Writer: Great salary and benefits

Senior Account Manager / Account Director: Great salary and bebefits

Subscribe to our email news alerts

PMHub

Add my company

emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...